Joshua M. V. Mammen

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Joshua M V Mammen, Joshua M.v. Mammen, Joshua Mammen, Joshua V. Mammen
Publication record
27 papers · 641 citations · H-index 11

PAPERS

Abstract RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial
20254 citationsauthor #12
Evolving Gender Parity of Industry Research Funding to Surgical Oncologists: An Open Payments Database Analysis
20243 citationsauthor #6
Open Payments Data Analysis of General and Fellowship-trained Surgeons Receiving Industry General Payments From 2016 to 2020
20236 citationsauthor #7
Age‐related next‐generation sequencing mutational analysis in 1196 melanomas
20232 citationsauthor #9
Surgical Management of Melanoma: Advances and Updates
202227 citationsauthor #2
Recent Evolution in the Management of Lymph Node Metastases in Melanoma
20213 citationsauthor #5
Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
201945 citationsauthor #13
Morbidity and mortality of synchronous hepatectomy with cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
201815 citationsauthor #7
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
2018103 citationsauthor #25
Prospective phase II multicenter trial of ablation after breast lumpectomy added to treat (ABLATE) breast cancer without radiation.
20180 citationsauthor #6
Comparison of terminal duct lobular units in the nipple areolar complex by tumor subtypes-the implication for nipple sparing mastectomy.
20170 citationsauthor #5
Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.
20166 citationsauthor #9
Abstract 2953: Notch signaling is a key pathway involved in drug resistance in melanoma cells
20161 citationsauthor #7
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
2016129 citationsauthor #24
Use of non-anthracycline adjuvant chemotherapy in triple-negative breast cancer: Review from a prospective registry.
20150 citationsauthor #8
Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression.
20152 citationsauthor #6
Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer
201512 citationsauthor #3
Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer.
20154 citationsauthor #7
Honokiol inhibits melanoma stem cells by targeting notch signaling
201583 citationsauthor #9
Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC).
201412 citationsauthor #7
Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway.
201426 citationsauthor #6
Chemotherapy-induced amenorrhea (CIA) risk associated with taxane/platinum-based chemotherapy in young (≤45 years) breast cancer patients.
20142 citationsauthor #8
Prospective evaluation of BRCA mutations in a large triple-negative breast cancer (TNBC) registry: Implications for germline testing.
20131 citationsauthor #11
Honokiol in Combination with Radiation Targets Notch Signaling to Inhibit Colon Cancer Stem Cells
2012102 citationsauthor #2
Secondary review of external histopathology on cutaneous oncology patients referred for sentinel lymph node biopsy: how often does it happen and is it worth it?
20123 citationsauthor #3
Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells.
201251 citationsauthor #8
Preclinical Development Honokiol in Combination with Radiation Targets Notch Signaling to Inhibit Colon Cancer Stem Cells
20120 citationsauthor #2

TIMELINE

2012 156 citations

2013 1 citations

2014 40 citations

2015 101 citations

2016 136 citations

2017 0 citations

2018 118 citations

2019 45 citations

2021 3 citations

2022 27 citations

2023 8 citations

2024 3 citations

2025 4 citations

Joshua M. V. Mammen

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT